News | April 04, 2022
USFDA grants priority review to Roche’s Actemra/RoActemra to treat Covid-19
If approved, it will be the first USFDA-approved immunomodulator for the treatment of Covid-19 in hospitalised patients
If approved, it will be the first USFDA-approved immunomodulator for the treatment of Covid-19 in hospitalised patients
New simplified structure and operational set-up supports Novartis strategy as a focused medicines company and is designed to power next phase of innovation, growth and productivity
The symposium was organized by the Gut Microbiota and Probiotic Science Foundation (India) and Medanta Institute of Education and Research, Gurugram, and Amity University, Gurugram
It aims to make the state-of-the-art modern and safe surgical care, typically available in super-speciality hospitals of big cities, accessible, affordable, standardized and integrated
Intas has developed a biosimilar of Lucentis, which is currently under Phase III global trial for submission in major countries including EMA & the US
Among patients with infectious virus at baseline, no patients who received Lagevrio had infectious virus at days 3, 5 or 10
Company announced that it is accelerating its investment in its Leaps by Bayer impact investment unit with more than 1.3 billion euros funding until end of 2024
The brand Azmarda fits well with JBCPL's overall strategy of strengthening its presence in the cardiology segment in India.
This state-of-art technology will help pulmonologists to diagnose lung cancer in the very early stages helping the patient get an early surgical resection
Yescarta is First CAR T-cell therapy to receive NCCN treatment guideline category 1 recommendation --
Subscribe To Our Newsletter & Stay Updated
